| Literature DB >> 28874460 |
Marta Martin-Lorenzo1, Paula J Martinez1, Montserrat Baldan-Martin1, Gema Ruiz-Hurtado1, Jose Carlos Prado1, Julian Segura1, Fernando de la Cuesta1, Maria G Barderas1, Fernando Vivanco1, Luis Miguel Ruilope1, Gloria Alvarez-Llamas2.
Abstract
Resistant hypertension (RH) affects 9% to 12% of hypertensive adults. Prolonged exposure to suboptimal blood pressure control results in end-organ damage and cardiovascular risk. Spironolactone is the most effective drug for treatment, but not all patients respond and side effects are not negligible. Little is known on the mechanisms responsible for RH. We aimed to identify metabolic alterations in urine. In addition, a potential capacity of metabolites to predict response to spironolactone was investigated. Urine was collected from 29 patients with RH and from a group of 13 subjects with pseudo-RH. For patients, samples were collected before and after spironolactone administration and were classified in responders (n=19) and nonresponders (n=10). Nuclear magnetic resonance was applied to identify altered metabolites and pathways. Metabolites were confirmed by liquid chromatography-mass spectrometry. Citric acid cycle was the pathway most significantly altered (P<0.0001). Metabolic concentrations were quantified and ranged from ng/mL malate to μg/mL citrate. Citrate and oxaloacetate increased in RH versus pseudoresistant. Together with α-ketoglutarate and malate, they were able to discriminate between responders and nonresponders, being the 4 metabolites increased in nonresponders. Combined as a prediction panel, they showed receiver operating characteristiccurve with area under the curve of 0.96. We show that citric acid cycle and deregulation of reactive oxygen species homeostasis control continue its activation after hypertension was developed. A metabolic panel showing alteration before spironolactone treatment and predicting future response of patients is shown. These molecular indicators will contribute optimizing the rate of control of RH patients with spironolactone.Entities:
Keywords: blood pressure; citric acid cycle; metabolomics; reactive oxygen species; spironolactone
Mesh:
Substances:
Year: 2017 PMID: 28874460 DOI: 10.1161/HYPERTENSIONAHA.117.09819
Source DB: PubMed Journal: Hypertension ISSN: 0194-911X Impact factor: 10.190